The incidence of non-functioning pancreatic neuroendocrine neoplasms (NF-PanNENs) has increased recently
1. Traditionally, surgery has been the treatment of choice for localized NF-PanNENs, although evidence has emerged that active surveillance could be advocated for most asymptomatic tumours no larger than 2 cm
2–7. However, the practice of active surveillance varies considerably and, contrary to current recommendations
8–10, many patients still undergo surgical resection
11–13.